Loading...
Found 21 results for chemotherapy
A listing of chemotherapy medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitors with Blinatumomab in Patients with Newly-Diagnosed Philadelphia Chromosome-Positive or Abl-Class Philadelphia Chromosome-Like B-Cell Acute Lymphoblastic Leukemia
S
Sandeep Batra, MD
This phase III trial compares the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy versus dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (PH+) or ABL-class Philadelphia chromosome-like (Ph-Like) B-Cell acute lymphoblastic leukemia (B-ALL). Blinatumomab is a bispecific antibody that …
Testing the Addition of the Anti-Cancer Drug Venetoclax And/Or the Anti-Cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed Kmt2A-Rearranged or Kmt2A-Non-Rearranged Leukemia
A
Amanda J. Saraf, DO
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged [R]) or without a KMT2A gene rearrangement (KMT2A-germline [G]). Venetoclax is in a class of medications called B-cell lymphoma-2 (Bcl-2) …
Risk stratified treatment for patients with newly diagnosed juvenile myelomonocytic leukemia: A Phase I/II non-randomized study of trametinib and azacitidine with or without chemotherapy
S
Sandeep Batra, MD
This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with juvenile myelomonocytic leukemia (JMML). Newly diagnosed lower-risk JMML patients will receive trametinib and azacitidine. High-risk JMML patients will receive trametinib, azacitidine, fludarabine, and cytarabine. THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with …
A Phase III Trial of One vs. Two Years of Maintenance Olaparib, with or without Bevacizumab, in Patients with BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy
J
Jessica Parker Metter
What is the purpose of this study?This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme …
A Phase II Trial Evaluating Chemotherapy Followed by Response-Based Reduced Radiation Therapy for Patients With Central Nervous System Germinomas
S
Sandeep Batra, MD
What is the purpose of this study?This phase II trial studies how well lower dose radiotherapy after chemotherapy works in treating children with central nervous system (CNS) germinomas. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Carboplatin is in a class …
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
S
Sandeep Batra, MD
What is the purpose of this study?Rhabdomyosarcoma is a type of cancer that occurs in the soft tissues in the body. This phaseutcomes in patients with very low risk rhabdomyosarcoma (VLR-RMS) while decreasing the burden of therapy using treatment with 24 weeks of vincristined dactinomycin (VA) and examines the use …
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
S
Sandeep Batra, MD
What is the purpose of this study?This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acuteyeloid leukemia with or without FLT3 mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and gemtuzumab ozogamicin, work in different ways to stop …
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
M
Marissa Just
What is the purpose of this study?This phase II trial studies how well combination chemotherapy works in treating patients withwly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Drugs used in chemotherapy regimens suchH-3 (vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, …
Detection of late subclinical cardiovascular disease in testicular cancer survivors exposed to cisplatin chemotherapy and bone marrow transplant
N
Nabil Adra, MD
Testicular cancer (TC) is diagnosed in young adult males between ages 18-39 and TC treatment involves the use of platinum therapy (CBCT) which can have long-term cardiovascular effects. We are looking at cholesterol and hormone changes, as well as blood vessel changes for coronary artery disease or blockages in the …
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
S
Sandeep Batra, MD
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab …
Please choose between Voice or SMS based delivery of verification code
or